KPV vs LL-37
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), three residues long. LL-37 is the sole human cathelicidin, a 37-residue amphipathic alpha-helical peptide released by proteolytic cleavage of the hCAP18 precursor encoded by the CAMP gene and expressed by neutrophils, monocytes and epithelial cells. Vendor pages set them against each other as rival antimicrobial peptides, which is where the comparison comes from; the published literature treats them as members of the same broad host-defence category rather than as competitors. No experiment has tested them against each other, in the same assay, animals or patients. Eight reviews name and describe both, most of them surveying host-defence or short peptides for gut inflammation, wound healing, antifungal or antiviral use, and none administered either compound. Their evidence bases are very different in size and maturity: LL-37 has controlled human trials and a documented pathogenic side, while KPV has no human trial of any kind.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has administered KPV and LL-37 to the same subjects, tested them in the same assay, or compared their potency under shared conditions. Searches of PubMed and Europe PMC across the tripeptide names Lys-Pro-Val and alpha-MSH(11-13) and the cathelicidin, hCAP18 and CAMP designations returned no comparative experiment. The eight located publications that engage both are reviews. A 2025 short review of host defence peptides for inflammatory bowel disease listed cathelicidins and the alpha-MSH-derived KPV in the same taxonomy and described both as downregulating the nuclear factor kappa B pathway and modulating cytokine release. A 2025 review of tripeptides in wound healing came closest to a direct contrast, comparing tripeptides as a class with larger peptides including LL-37 and arguing that the short peptides retain potency with greater formulation adaptability while larger linear peptides such as LL-37 show strong antimicrobial activity but face delivery and stability challenges. That is an argument about peptide size classes, not a measured comparison of these two molecules. Older reviews of antimicrobial, antifungal and antiviral host peptides catalogue LL-37 and the alpha-MSH C-terminal tripeptide alongside each other, each drawing on separate primary studies. Any statement that one is more potent, safer or broader in spectrum than the other is therefore an inference across unrelated experiments.
The 8 publications that cover both
- 01Review2025
Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
Rodrigues JM, et al. · Drug Discov Today · short review of host defence peptides as candidate therapeutics for inflammatory bowel disease
The review grouped cathelicidins, including LL-37 derivatives and the shortened KR-12 fragment, with alpha-melanocyte-stimulating hormone-derived peptides exemplified by KPV, within a single taxonomy of host defence peptides for inflammatory bowel disease. Both classes were described as acting through immunoregulatory mechanisms that downregulate the nuclear factor kappa B pathway, modulate cytokine release and restore homeostasis. Neither peptide was administered and no comparison between them was drawn.
- 02Review2025
Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
Adnan SB, et al. · Int J Med Sci · review of tripeptides in wound healing and skin regeneration, with a discussion section contrasting tripeptides against larger peptides of 7, 37 and 72 amino acids
This review contains the closest thing to a direct contrast in the literature, at the level of peptide size rather than of these two molecules. It compared tripeptides with larger peptides including the cathelicidin-derived LL-37, arguing that tripeptides maintain therapeutic potency while remaining more adaptable in formulation, whereas larger linear peptides such as LL-37 may exhibit strong antimicrobial activity but often face challenges of delivery and stability. No experiment was performed and no potency measurement was reported for either peptide.
- 03Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of therapeutic peptides across aesthetic, metabolic and endocrine use, with a healing and regeneration section listing KPV and LL-37 among emerging peptides
The review described KPV as a short anti-inflammatory peptide derived from alpha-melanocyte-stimulating hormone whose preclinical record links it to gastrointestinal protection, mucosal healing and epithelial wound repair, and noted that in a colitis-associated cancer model KPV reduced tumour number and size where PepT1 was present. It described LL-37 as the only human cathelicidin, influencing epithelial barrier integrity, intestinal inflammation and wound repair beyond its antimicrobial action, and characterised it as promising yet experimental. The authors concluded that further studies are needed before most of the newer peptides can be used safely in humans.
- 04Review2024
Bioactive peptides and proteins for tissue repair: microenvironment modulation, rational delivery, and clinical potential
Hao ZW, et al. · Mil Med Res · review of bioactive peptides and proteins for tissue repair, covering microenvironment modulation, delivery design and clinical translation
The review reported LL-37 among the peptides with clinical wound-healing evidence, citing a randomised placebo-controlled trial in hard-to-heal venous leg ulcers that enhanced healing at specific concentrations with no adverse effects reported, and noting an ongoing trial in diabetic foot ulcers. KPV appeared in the delivery section, as the anti-inflammatory component of a glucose-responsive layer-by-layer film that also carried epidermal growth factor for tissue repair. The two peptides were discussed in separate contexts.
- 05Review2021
Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment
Zhang W, et al. · Front Bioeng Biotechnol · review of oral delivery systems for biologics in inflammatory bowel disease, including a table of therapeutic peptides applied in inflammatory bowel disease treatment
The review tabulated both peptides as candidate inflammatory bowel disease therapeutics, listing KPV with PepT1 interaction and an oral route and cathelicidin with a Toll-like receptor mechanism and an intracolonic route. Its substantive discussion concerned KPV delivery, summarising polymeric nanoparticles, hyaluronic acid-functionalised nanoparticles within a chitosan hydrogel, and KPV used as a PepT1-targeting ligand on nanoparticles carrying another drug. The comparison between the two peptides was categorical rather than experimental.
- 06Review2020
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer DK, et al. · Front Immunol · review of host-derived antifungal peptides and immunotherapeutics, covering cathelicidins, defensins, histatins and melanocortin-derived peptides
The review covered LL-37 extensively among host-derived antifungal peptides and separately described CZEN-002, a synthetic octapeptide built from the alpha-MSH C-terminal tripeptide KPV with a cysteine linker. It reported that CZEN-002 was candidacidal against Candida albicans, Candida krusei and Candida glabrata at sub-millimolar concentrations and that it was not membranolytic, a mechanism distinct from the membrane disruption attributed to cathelicidins.
- 07Review2019
Human Antimicrobial Peptides as Therapeutics for Viral Infections
Ahmed A, et al. · Viruses · review of human antimicrobial peptides with antiviral activity, including cathelicidin LL-37, defensins and neuroendocrine peptides
The review identified the C-terminal tripeptide KPV as the active component of alpha-melanocyte-stimulating hormone and reported that both the parent peptide and KPV inhibited HIV expression in chronically infected monocytic cells and acutely infected monocyte-derived macrophages, with inhibition of nuclear factor kappa B activation. LL-37 was covered at much greater length as the human cathelicidin with antiviral activity across several virus families. No experiment compared the two.
- 08Review2014
Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide
Singh M, et al. · Biomed Res Int · review of alpha-melanocyte-stimulating hormone as an anti-inflammatory antimicrobial peptide, with a comparative table of human antimicrobial peptides
The review tabulated cathelicidin LL-37 among human antimicrobial peptides with its sequence, structure and cellular sources, and separately synthesised the evidence that alpha-MSH and its C-terminal tripeptide KPV inhibit Candida albicans, Escherichia coli and Staphylococcus aureus. It reported that fragments of alpha-MSH lacking KPV did not show substantial antimicrobial activity, and that the tripeptide required for anti-inflammatory activity is also the sequence required for direct antimicrobial efficacy. The two peptides were placed in one framework without being tested against each other.
Side by side.
| KPV | LL-37 | |
|---|---|---|
| Evidence maturity | Preclinical only | Early clinical |
| Studies cited here | 15 | 17 |
| Published 2023 or later | 6 | 13 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | The three-residue C-terminal fragment of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13). It is a fragment of an endogenous hormone rather than an independently expressed peptide, and what is sold is chemically synthesised. | The sole human cathelicidin, a 37-residue amphipathic alpha-helical peptide released by proteolytic cleavage of the hCAP18 precursor encoded by the CAMP gene and expressed by neutrophils, monocytes and epithelial cells. |
| Mechanism as described in the literature | Suppression of nuclear factor kappa B signalling and cytokine reduction, with uptake into intestinal epithelial and immune cells through the PepT1 di/tripeptide transporter identified as the route of its anti-inflammatory effect. Antimicrobial activity is attributed to the same tripeptide sequence within alpha-MSH. | Direct membrane permeabilisation of microbes, neutralisation of lipopolysaccharide, and receptor-mediated chemotaxis of monocytes, neutrophils and T cells through FPR2/FPRL1. Transcription of the CAMP gene is directly induced by 1,25-dihydroxyvitamin D3. |
| Size and shape of the evidence base | Small and narrow. The literature concentrates on rodent colitis and gut barrier repair and on keratinocyte protection, and a substantial share of recent output is formulation science, using nanoparticles, hydrogels and films rather than generating new pharmacology. | Large and broad. It spans antimicrobial and antibiofilm activity, vitamin D-driven gene induction, antiviral work, chemotaxis, wound healing and angiogenesis, neutrophil extracellular trap biology, and its role as an autoantigen in atherosclerosis. |
| Best-characterised finding | A 2008 study in Gastroenterology showing that KPV entered intestinal epithelial and immune cells through the PepT1 transporter and that this uptake accounted for its anti-inflammatory effect in two mouse colitis models. | A 2000 study identifying formyl peptide receptor-like 1 as the receptor through which LL-37 chemoattracts human monocytes, neutrophils and T cells, which established a receptor-mediated immunological role distinct from direct microbial killing. |
| Human data | None. No human clinical trial of KPV has been published for colitis, wound healing, skin inflammation or any other indication, so human dose, route and safety profile are unestablished. | Present, and mixed. A phase IIb randomised placebo-controlled trial in hard-to-heal venous leg ulcers found no significant improvement in healing on its full-cohort analysis; a randomised double-blind trial of a topical cream in diabetic foot ulcers reported a greater increase in granulation index; a randomised trial of an oral formulation reported shorter viral RNA negative conversion time in COVID-19 inpatients. |
| Evidence maturity | Preclinical only. Every result comes from cell culture or rodent models, and much of it from engineered delivery vehicles rather than the plain peptide. | Early clinical, but narrowly so. The controlled human trials used topical or oral formulations only; there is no human data on systemic or injectable administration and no approved product. |
| Safety signals reported | No adverse-event literature exists, because no human study has been conducted. The reported limitation is chemical rather than toxicological: free KPV is unstable in aqueous and rectal administration, which is why the recent work engineers delivery systems around it. | Substantial and specific. LL-37 is implicated as a pathogenic driver in rosacea, psoriasis and atherosclerosis; injection reproduces rosacea-like cutaneous inflammation in mice, and a circulating LL-37-ApoB-100 complex correlated with angiographic coronary disease severity in a two-centre observational study. Its switch between protective and inflammatory behaviour is concentration- and context-dependent and not adequately characterised. |
| Basis of most marketing claims | Extrapolation from engineered nanoparticle, hydrogel and microneedle formulations to the unformulated peptide that is sold, and from alpha-MSH fragment studies to KPV as an antimicrobial in its own right. | Extrapolation from broad in vitro antimicrobial and antibiofilm potency to systemic use, when the only controlled human evidence is topical and oral, the largest topical trial was negative on its primary analysis, and the same peptide is described elsewhere as a driver of inflammatory disease. |
And what it does not.
The published record does not support a ranking between these two peptides, because no experiment has ever run them together. The reviews that name both place them in the same host-defence category and then describe each from separate primary literatures using different pathogens, cells, models and endpoints. Read on their own terms, the two are not equivalent in maturity. LL-37 has decades of mechanistic work, a receptor, a vitamin D-dependent induction pathway and three controlled human trials, the largest of which was negative on its primary analysis; it also has a documented pathogenic side in rosacea, psoriasis and atherosclerosis that any account of it has to carry. KPV has a coherent and reproducible anti-inflammatory mechanism in rodent colitis through the PepT1 transporter, no human trial of any kind, and a recent literature dominated by delivery systems built to compensate for the free peptide's instability. Neither has controlled human evidence for the antimicrobial or skin-repair uses that prompt the comparison.
Common questions.
- Has any experiment compared KPV and LL-37 in the same assay?
No. Searches of PubMed and Europe PMC across the tripeptide names Lys-Pro-Val and alpha-MSH(11-13) and the LL-37, cathelicidin, hCAP18 and CAMP designations returned no study that tested both, whether for antimicrobial potency, anti-inflammatory effect or wound healing. The eight publications that engage both are reviews that catalogue them among host defence or short peptides. Claims that one is the better antimicrobial peptide are assembled from separate experiments with different organisms, concentrations, media and readouts.
- Is KPV antimicrobial in the same way LL-37 is?
The mechanisms described in the literature are different. LL-37 is reported to permeabilise microbial membranes directly and to neutralise lipopolysaccharide. The antimicrobial evidence attached to KPV comes from work on alpha-melanocyte-stimulating hormone and its fragments, where activity against Candida albicans was linked to induction of cyclic AMP rather than membrane disruption, and a review of antifungal peptides described a KPV-derived octapeptide as candidacidal but explicitly not membranolytic.
- Which of the two has been tested in people?
Only LL-37, and only in topical and oral formulations. A phase IIb randomised placebo-controlled trial in hard-to-heal venous leg ulcers found no significant improvement in healing across the full cohort. A randomised double-blind trial of a topical cream in mildly infected diabetic foot ulcers reported a greater increase in granulation index without a significant reduction in cytokines or bacterial colonisation. A randomised trial of an oral formulation reported shorter viral RNA negative conversion time in COVID-19 inpatients. KPV has no published human trial.
- Why is LL-37 described as both protective and harmful?
Because the published record supports both descriptions depending on concentration and context. The same peptide that kills microbes, disrupts biofilms and recruits immune cells is also implicated as a pathogenic driver: injecting it reproduces rosacea-like inflammation in mice, it functions as an autoantigen in atherosclerotic cardiovascular disease, and a circulating LL-37-ApoB-100 complex tracked with coronary disease severity in observational work. Reviews describe the switch between these behaviours as depending on concentration, receptor binding, disease stage and local microenvironment, and as not adequately characterised.
- Why does so much KPV research involve nanoparticles and hydrogels?
Because the free peptide is unstable in aqueous solution and on rectal administration, which compromised efficacy in a rat colitis experiment and prompted the development of stabilised carriers. The recent literature is accordingly dominated by hyaluronic acid-functionalised nanoparticles, thiolated polyglutamic acid hydrogels, mucoadhesive gels and glucose-responsive films. Results obtained with those engineered systems describe the formulation as much as the peptide, and do not transfer to unformulated KPV.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.